B007 clinical trials
How each study uses B007 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the B007 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- B007
- 4
Studies by the year they started
4 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Shanghai Jiaolian Drug Research and Development Co., Ltd (4)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4, 3 in phase 3
Studies that test B007, phase 3 first.
- Dec 2026A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.Phase 2/3 · Shanghai Jiaolian Drug Research and Development Co., Ltd
- Dec 2026A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.Phase 2/3 · Shanghai Jiaolian Drug Research and Development Co., Ltd
- Dec 2026A Clinical Study of B007 in the Treatment of Pemphigus.Phase 2/3 · Shanghai Jiaolian Drug Research and Development Co., Ltd
- Dec 2026A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous NephropathyPhase 1 · Shanghai Jiaolian Drug Research and Development Co., Ltd
Studies
Open first, then newest update. How each study uses B007 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.RecruitingPhase 2/3Shanghai Jiaolian Drug Research and Development Co., LtdNCT06447597Written as B007
- A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.RecruitingPhase 2/3Shanghai Jiaolian Drug Research and Development Co., LtdNCT06470191Written as B007
- A Clinical Study of B007 in the Treatment of Pemphigus.RecruitingPhase 2/3Shanghai Jiaolian Drug Research and Development Co., LtdNCT06454357Written as B007
- A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous NephropathyRecruitingPhase 1Shanghai Jiaolian Drug Research and Development Co., LtdNCT05668403Written as B007